Pharmed Limited Unlisted Shares
Pharmed: Innovating for Health, One Molecule at a Time
For over 70 years, Pharmed has been a steadfast force in the Indian pharmaceutical landscape, crafting evidence-based, high-quality nutraceutical and pharmaceutical products that have transformed lives. Their dedication to innovation and filling therapeutic gaps has earned them respect and trust from both the medical community and patients alike.
A Legacy of Firsts:
Pharmed’s commitment to pioneering solutions shines through in their impressive track record:
Supracal®: The first Indian brand to introduce optimally absorbed, acid-independent Calcium Citrate, paving the way for better bone health.
Absolut®: A first-mover in combining green tea’s benefits with essential nutrients, empowering chronic disease management.
Tendocare®: Revolutionizing tendinopathy treatment by addressing the core issue of tendon degeneration.
MGD3®: Making bioavailable magnesium readily accessible, tackling subclinical magnesium deficiency and optimizing Vitamin D absorption.
Cartigen®: Pioneering Glucosamine in India, offering joint health support and hindering osteoarthritis progression.
FOL 123 MF™: Ensuring complete maternal health through a unique combination of iodine and DHA.
Synertab®: The first Indian synovitis treatment, enhancing primary therapy and improving outcomes for arthropathies.
Prolife®: Introducing a safe and unique endogenous progesterone support formula for effective obstetric and gynaecological support.
OsteoCync™: Redefining joint care with the first-ever formula addressing subchondral bone loss in osteoarthritis, effectively minimizing cartilage loss and inflammation.
A Trusted Name Across Specialties:
Pharmed’s expertise extends across various therapeutic areas, including:
- Women’s health
- Reproductive health
- Joint, bone, and tendon health
- Pain management
- Cardio-diabetic health
- Ear, nose, and throat health
- Urogenital health
- Digestive health
- Immune health
- General health
Leading the Way with Vision:
At the helm of this visionary company are:
Suneet Aurora: Chairman and Managing Director, bringing his expertise in economics and legal studies to guide Pharmed’s future.
S.N. Agarwal: Chairman of Bhoruka Group, lending his vast industrial experience and leadership to the board.
Dr. Jagdish Chinappa: Renowned paediatric consultant, ensuring child-centric considerations are integrated into Pharmed’s initiatives.
With a rich legacy of innovation, a diverse therapeutic portfolio, and a leadership team committed to progress, Pharmed stands poised to continue shaping the future of healthcare in India and beyond.
Buy Pharmed Limited Unlisted Shares, Sell Pharmed Limited Unlisted Shares, Buy Pharmed Unlisted Shares, Sell Pharmed Unlisted Shares
PHARMED Limited share Price, Unlisted Shares, Pre IPO-Stock – Company Overview
Pharmed Limited, headquartered in India’s Silicon Valley, Bangalore, is now one of the fastest-growing pharmaceutical companies in the country. For over seven decades, since 1946, Pharmed has been consistently carrying on its legacy of ‘Caring for India’ and helping millions of users improve quality of life. In a journey that started over 70 years ago, Pharmed has become a name to be reckoned with among the Indian medical fraternity, with its innovative range of products that have changed disease management by enhancing lifestyle. Evidence-based pharmaceutical and nutraceutical products are at the heart of Pharmed, and are regularly promoted among Gynaecologists, Orthopaedic Surgeons, Physicians, Dermatologists and Otolaryngologists, for our prescription driven Business.
Our quest to cater unmet needs across specialized therapy areas and our fervent belief in quality and innovative formulations have created opportunities for Pharmed to produce several ‘First time in India’ brands based on strong evidence. Our nationwide sales and marketing force, supported by an efficient distribution network and well-structured support departments stationed at our state-of-the-art Corporate office has made Pharmed an eminent name in the Indian Pharmaceutical Market.
Pharmed Limited Delisted Share Details As of March 31, 2023
| Pharmed Limited Outstanding Shares: | 4306200 |
| Face Value of Pharmed Limited Delisted Share: | Rs.2 Per Equity Share |
| ISIN of Pharmed Limited Delisted Share: | INE0EEI01017 |
| Lot Size of Pharmed Limited Share: | 100 |
| Pharmed Limited Share Price: | Best In Industry |
| PAN Number of Pharmed Limited : | AAACP2191A |
PHARMED Limited Incorporation Details
| PHARMED Limited CIN Number | U24230MH1946PLC005121 |
| PHARMED Limited Registration Date | 10-08-1946 |
| Category / Sub-Category of PHARMED Company Limited | Company Limited by Shares / Indian Non Government Company |
| PHARMED Limited Registered Office Address | “Pharmed House” ,141, walchand hirachand marg, Bombay – 400001 |
Board of Directors of PHARMED Limited
| Board of Directors Constituents | Post |
| Mr. S.N. Agarwal | Independent Director |
| Dr. Jagdish Chinnappa | Independent Director |
| Mr. K.K. Aurora | Chairman Emeritus , Non Executive Director |
| Mr. Suneet Aurora | Chairman & Managing Director |
| Mr. K.L. Kapoor | Whole Time Director |
| Mr. V. Krishnamurthy | Whole Time Director |
| Mr. N.B. Shroff | Whole Time Director |
| Mrs. Yogesh Saran Aurora | Whole Time Director |
Business Activities
| Name and Description of main products/services | % to the total turnover of the Company |
| Pharmaceutical and Nutraceutical products | 100.00% |
PHARMED Company Limited’s Particulars of Holding, Subsidiaries, & Associate Companies
| Name of the Company | Subsidiary / Associate | % of shares held |
| Sunora Investments Private Limited | Subsidiary | 100.00% |
PHARMED Limited Balance Sheet (In Rs. Crores)
| Particulars | As at 31 March 2023 | As at 31 March 2022 |
| ASSETS | ||
| 1) Non current assets | ||
| a)Property, Plant, and Equipment | ||
| i) Property, Plant, and Equipment | 47.54 | 49.73 |
| ii) Intangible Assets | 0.10 | 0.12 |
| iii) Capital work in progress | 0.31 | 0.31 |
| b) Goodwill on consolidation | 29.11 | 29.11 |
| c) Non current investments | 141.06 | 113.72 |
| c) Deferred Tax Assets (Net) | 2.44 | 2.55 |
| d) Other Non-Current Assets | 0.58 | 0.49 |
| Total non current assets | 221.14 | 196.03 |
| Current Assets | ||
| a) Inventories | 31.02 | 32.24 |
| b) Trade Receivables | 18.83 | 17.26 |
| c) Cash and Cash Equivalents | 12.73 | 4.42 |
| d) Short Term Loans and Advances | 6.06 | 12.26 |
| Total current assets | 68.64 | 66.18 |
| Total Assets | 289.78 | 262.21 |
| EQUITY AND LIABILITIES | ||
| EQUITY | ||
| a) Equity Share capital | 0.86 | 0.86 |
| b) Other equity | 230.19 | 198.74 |
| Total Equity | 231.05 | 199.60 |
| LIABILITIES | ||
| Non-current Liabilities | ||
| a) Other Long Term liabilities | 4.26 | 2.83 |
| b) Long Trem Provisions | 4.99 | 4.53 |
| Total non current liabilities | 9.25 | 7.36 |
| Current liabilities | ||
| a)Trade payables | ||
| Total outstanding dues of micro and small Enterprises | 20.24 | 24.06 |
| Total outstanding dues of creditors other than micro and small enterprises | 3.71 | 12.56 |
| b) Other current liabilities | 4.27 | 5.81 |
| c) Short Term Provisions | 21.26 | 12.82 |
| Total current liailities | 49.48 | 55.25 |
| Total liabilities | 58.73 | 62.61 |
| Total Equity and liabilities | 289.78 | 262.21 |
PHARMED Limited Profit & Loss Statement (In Rs. Crores)
| PARTICULARS | 2023 | 2022 |
| Revenue from Operations | 425.99 | 350.19 |
| Other Income | 9.98 | 9.45 |
| Total Revenue | 435.97 | 359.64 |
| Expenses | ||
| Purchase of Stock in Trade | 127.66 | 100.37 |
| Changes In Inventories of Stock in Trade | 1.22 | -6.25 |
| Employee Benefits Expense | 129.97 | 97.79 |
| Finance Cost | 0.36 | 0.30 |
| Other Expenses | 130.39 | 110.09 |
| Depreciation and Amortisation Expense | 3.27 | 2.32 |
| Total Expenses | 392.87 | 304.62 |
| Profit before Tax | 43.10 | 55.02 |
| Tax Expense | ||
| 1) Current Tax | 10.03 | 13.08 |
| 2) Deferred Tax | 0.10 | -0.39 |
| Profit for the year | 32.97 | 42.33 |
| Earnings per Equity share (Face Value Per Share) | ||
| a) Basic (Rs.) | 76.54 | 98.27 |
| b) Diluted (Rs.) | 76.54 | 98.27 |
PHARMED Limited’s Cash Flow Statement (In Rs. Crores)
| Particulars | 31st March 2023 | 31 March 2022 |
| A. Cash Flow from Operating Activities | ||
| Profit/(Loss) Before Tax | 43.10 | 55.02 |
| Adjustments for: | ||
| Depreciation and amortisation expenses | 3.27 | 2.32 |
| Finance cost | 0.36 | 0.30 |
| Interest Income | -0.81 | -0.70 |
| Net(gain) / Loss on sale of Investments | -8.62 | -7.83 |
| Rental Income from Investment Properties | -0.04 | -0.04 |
| (Gain) / Loss on sale of Asset | 0.01 | 0.01 |
| Cash generated from operations before working capital changes | 37.27 | 49.08 |
| Working capital changes | ||
| Adjustments for (increase)/decrease in operating Assets | ||
| Inventories | 1.22 | -6.25 |
| Trade receivables | -1.57 | -0.93 |
| Short term loan and advances | 5.06 | -5.23 |
| Long term Loans and advances | – | 1.20 |
| Other non current assets | -0.09 | -0.16 |
| Adjustments for (increase)/decrease in operating liabilities | ||
| Trade payables | -12.66 | 12.56 |
| Other current liabilities | -1.54 | 2.73 |
| Other Long term liabilities | 1.43 | 0.30 |
| Long term provisions | 0.44 | 0.64 |
| Short Term provisions | 8.44 | -0.07 |
| Operating profit after working capital changes | 38.00 | 53.87 |
| Income tax paid, net of refunds | -8.99 | -14.12 |
| Net cash generated from operating activities | 29.01 | 39.75 |
| Cash flows from investing activities | ||
| Capital Expenditure on Fixed Assets, including capital advances | -1.13 | -41.97 |
| Proceeds from sale of property, plant & equipment | 0.06 | 0.55 |
| Purchase of long term investments | -104.55 | -49.48 |
| Proceeds from sale of long term investments | 85.83 | 52.13 |
| Interest Received | 0.81 | 0.70 |
| Rental Income Received | 0.04 | 0.04 |
| Net cash used in investing activities | -18.94 | -38.03 |
| Cash flows from financing activities | ||
| Dividend paid | -0.36 | -0.30 |
| Finance cost | -1.51 | -3.01 |
| Tax on Dividend | ||
| Net cash used in financing activities | -1.87 | -3.31 |
| Net increase/ (decrease) in cash and cash equivalent | 8.20 | -1.59 |
| Add: Cash and Cash Equivalent at beginning of year | 4.35 | 5.94 |
| Cash and cash equivalents as at end of year | 12.55 | 4.35 |
| Cash and Cash Equivalent comprise the following | ||
| Cash on hand | 0.08 | 0.16 |
| Balance with bank | ||
| In Current Account | 12.65 | 4.27 |
| Total | 12.73 | 4.43 |
PHARMED Limited Key Financial Ratios ( Standalone)
| Particulars | 31-Mar-23 | 31-Mar-22 |
| Current Ratio (in times) | 1.4 | 1.21 |
| Debt-Equity Ratio (in times) | 0 | 0 |
| Debt Service Coverage Ratio (in times) | 0 | 0 |
| Return on Equity Ratio (in %) | 14.44% | 21.41% |
| Inventory Turnover Ratio (in times) | 13.47 | 12.03 |
| Trade Receivables Turnover Ratio (in times) | 23.61 | 20.85 |
| Trade Payable Turnover Ratio (in times) | 4.22 | 3.31 |
| Net Capital Turnover Ratio (in times) | 27.45 | 26.89 |
| Net Profit Ratio (in %) | 7.77% | 12.08% |
| Return on investment | 6.74% | 7.57% |
| Return on Capital Employed Ratio (in %) | 19.00% | 28.00% |
PHARMED Limited share Dividend History
| Particulars | 2023 | 2022 |
| Dividend per Share | 3.5 | 3.5 |
| Retained Earnings (In Rs. Crores) | 228.4 | 196.81 |
PHARMED Limited Recent Financial Performance for FY 2023
Revenue from Operations: Revenue increased by ₹75.80 crores from 2022 to 2023, indicating potential growth in the core business.
Other Income: Other income remained relatively stable, with a slight increase from ₹9.45 crores in 2022 to ₹9.98 crores in 2023.
Total Revenue: Total revenue increased by ₹76.33 crores from 2022 to 2023, reflecting both core business growth and stable other income.
Total Expenses: Total expenses increased from ₹304.62 crores in 2022 to ₹392.87 crores in 2023, possibly due to increased costs.
Profit before Tax: Profit before tax decreased by ₹11.92 crores from 2022 to 2023, indicating lower pre-tax profitability in 2023.
Profit for the Year: The profit for the year decreased by ₹9.36 crores from 2022 to 2023.
Earning per Equity Share – Basic and Diluted: Basic and diluted earnings per equity share decreased significantly from ₹98.27 in 2022 to ₹76.54 in 2023, indicating reduced earnings per share.
